Assessment of pioglitazone and proinflammatory cytokines during buprenorphine taper in patients with opioid use disorder.

ABSTRACT:

Background

Preliminary evidence suggested that the PPARγ agonist pioglitazone reduces opioid-withdrawal symptoms, possibly by inhibiting increases in proinflammatory cytokines.

Methods

A randomized, placebo-controlled clinical trial was conducted utilizing two different study designs (entirely outpatient, and a combination of inpatient and outpatient) to evaluate the safety and efficacy of pioglitazone as an adjunct medication for people with opioid physical dependence undergoing a buprenorphine taper. Participants were stabilized on buprenorphine/naloxone (sublingual, up to 16/4 mg/day), then randomized to receive oral pioglitazone (up to 45 mg/day) or placebo before, during, and after buprenorphine taper. Outcome measures included the Subjective Opiate Withdrawal Scale (SO

SUBMITTER: Schroeder JR 

PROVIDER: S-EPMC7286070 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature